Clinical Trial Update: A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of intranasal racemic ketamine (SLS-002) in adults with major depressive disorder at imminent risk of suicide has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Suicidal Ideation

Drugs mentioned

• SLS-002

Snippet

Sponsor: Seelos Therapeutics, Inc. | Conditions: Depressive Disorder, Major, Suicidal | Phase 2 | Status: COMPLETED